YMAB | tickerfilter.com

Fundamental analysis

24%

Profitability 25%

Dept financing 5%

Liquidity 75%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-16.53%

1 Month

-18.02%

3 Months

-36.60%

6 Months

-31.00%

1 Year

31.64%

2 Year

72.86%

Key data

Stock price

$13.60

P/E Ratio

-25.91

DAY RANGE

$8.50 - $13.60

EPS

-$0.56

52 WEEK RANGE

$6.85 - $20.90

52 WEEK CHANGE

$21.94

MARKET CAP

637.794 M

YIELD

N/A

SHARES OUTSTANDING

44.570 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/11/2024

BETA

1.51

PUBLIC FLOAT

AVERAGE 10 VOLUME

$423,854

AVERAGE 30 VOLUME

$300,699

Company detail

CEO: Thomas Gad
Region: US
Website: ymabs.com
Employees: 150
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Y-mAbs Therapeutics, Inc. focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment of cancer in the United States. The company is developing DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor. GD2-GD3 vaccine that is in Phase II clinical trial for the. treatment of Stage 4 high-risk neuroblastoma.

YMAB - Y-mAbs Therapeutics, Inc.